2025 was a challenging year for Corcept Therapeutics Inc. (CORT), as its lead drug candidate, Relacorilant, was denied FDA approval for hypertension secondary to hypercortisolism, abruptly disrupting its near-term growth story. Shares, which had climbed past $100 early in the year, fell to about $35 by year-end, raising investor concerns.
Fast forward to today, and the same drug candidate has secured FDA approval for an alternate indication, sparking renewed optimism. Could this approval mark a turning point for Corcept and its stock?
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com